37
CANCER PAIN MANAGEMENT PAMELA M. SUTTON, M.D. FAAHPM DECEMBER 2013

CANCER PAIN MANAGEMENT PAMELA M. SUTTON, M.D. FAAHPM DECEMBER 2013

Embed Size (px)

Citation preview

CANCER PAIN MANAGEMENT

PAMELA M. SUTTON, M.D. FAAHPMDECEMBER 2013

“TOTAL PAIN”

“EVERYTHING HURTS”

• PHYSICAL PAIN

• EMOTIONAL PAIN

• SOCIAL PAIN

• SPIRITUAL PAIN

PAIN ASSESSMENT

PATIENT RATES INTENSITY/SEVERITY OF PAIN ON SCALE OF ZERO TO TEN

• LOCATION• QUALITY (ACHING, BURNING,

SHOOTING)• DURATION (INTERMITTENT OR

CONTINUOUS)• WHAT MAKES PAIN BETTER/WORSE

CAUSES OF PHYSICAL PAIN IN CANCER

• Bone Metastases-50%

• Nerve Injury(neuropathic)or compression-25%

• Cancer treatments-19%

NOCICEPTIVE

vs.

NEUROPATHIC PAIN

TREATMENT OF PHYSICAL PAIN

• TREAT UNDERLYING ILLNESS

• ELEVATE PAIN THRESHOLD

• INTERRUPT PAIN TRANSMISSION

WORLD HEALTH ORGANIZATION 3 STEP METHOD FOR CANCER PAIN RELIEF

(“Analgesic Ladder”)

• STEP 1. “NON-OPIOID” +/- ADJUVANT If pain persists or worsens, go to:

• STEP 2. MILD OPIOID +/- NON-OPIOID +/-

ADJUVANT If pain persists or worsens, go to:

• STEP 3. STRONG OPIOID +/- NON

OPIOID+/-ADJUVANT

ANALGESIC LADDER

ORAL MEDICATION IS PREFERRED

EASE OF ADMINISTRATION

STEADY BLOOD LEVELS

SAFETY

ANALGESIC LADDER

OPIOIDS DO NOT ALWAYS RELIEVE PAIN!

NON-OPIOID ADJUVANTS AND/OR OTHER PAIN METHODS MAY BE NECESSARY.

ANALGESIC LADDER

PAIN TREATMENT SUCCESSFUL IN 90% OF PATIENTS WITH PROPER MEDICATION USE

WORLD HEALTH ORGANIZATION 3 STEP METHOD FOR CANCER PAIN RELIEF

(“Analgesic Ladder”)

• STEP 1. “NON-OPIOID” +/- ADJUVANT If pain persists or worsens, go to:

• STEP 2. MILD OPIOID +/- NON-OPIOID +/-

ADJUVANT If pain persists or worsens, go to:

• STEP 3. STRONG OPIOID +/- NON

OPIOID+/-ADJUVANT

NON-OPIOID ANALGESIC

PARACETAMOL 500-1000 MG EVERY 4-6 HOURS

• Advantages: Available, cheap,

effective for mild pain.

• Disadvantages: Potential liver toxicity.

Not anti-inflammatory.

Not best choice for bone pain.

NON-OPIOID ANALGESICS

NSAID’S

• Advantages: Anti-inflammatory effects helpful for bone pain. Dosage may be less frequent than paracetamol.• Disadvantages: Potential GI/renal side effects and interference with platelet function.

NSAIDS• SALICYLATES

Aspirin• PROPRIONIC ACIDS

Ibuprofen--every 6 hours; liquid

Naproxen--every 12 hours• ACETIC ACIDS

Diclofenac--every 8 hours

Ketorolac (Toradol)--oral or

parenteral; short term use only

NSAIDS

COX 2 INHIBITORS• Celecoxib

• Less GI toxicity (not perfect);• Less anti-platelet activity• Potential Renal/Cardiovascular Toxicity

OPIOIDS1) CODEINE, MORPHINE

2) SEMISYNTHETIC

HYDROCODONE

BUPRENORPHINE (MIXED AGONIST/

ANTAGONIST)

3) SYNTHETIC

METHADONE (DOLOPHINE)

FENTANYL (DURAGESIC)

TRAMADOL

CONCERNS ABOUT OPIOIDS

1. ADDICTION

Physical Dependence and Psychological Craving

2. TOLERANCE

Rarely a practical problem. Dose can be

increased if tolerance occurs.

3. RESPIRATORY DEPRESSION

Rarely a problem when appropriate dose of oral

narcotic is titrated to level of pain.

CONCERNS ABOUT OPIOIDS

4. LETHARGY Sleepiness may occur in first hours/days but usually improves. 5. NAUSEA Occurs in less than half of patients. May

resolve. 6. CONSTIPATION Frequent problem--should be anticipated with

stool softener/laxative on a daily basis. Avoid bulk laxatives.

WORLD HEALTH ORGANIZATION 3 STEP METHOD FOR CANCER PAIN RELIEF

(“Analgesic Ladder”)

• STEP 1. “NON-OPIOID” +/- ADJUVANT If pain persists or worsens, go to:

• STEP 2. MILD OPIOID +/- NON-OPIOID +/-

ADJUVANT If pain persists or worsens, go to:

• STEP 3. STRONG OPIOID +/- NON

OPIOID+/-ADJUVANT

POSSIBLE STEP TWO OPIOIDS (for moderate pain)

• CODEINE• TRAMADOL • HYDROCODONE

STEP TWO OPIOIDS

CODEINE

• 30 mg orally is approximately equal in

analgesic effect to 650 mg of aspirin.

• When 30 mg codeine and 650 mg aspirin are combined, the analgesic effect equals or exceeds 60 mg codeine.

STEP TWO OPIOIDS

HYDROCODONE

• May be packaged with paracetamol or ibuprofen. Beware of associated toxicity.

STEP TWO OPIOIDS

TRAMADOL

• Synthetic mu agonist opioid

• Reportedly exerts additional analgesic effect by inhibition of serotonin and noradrenaline reuptake.

STEP THREE OPIOIDS(for severe pain)

• MORPHINE

• METHADONE (Dolophine)

• FENTANYL (Duragesic)

• BUPRENORPHINE

STEP THREE OPIOIDS

MORPHINE PROTOTYPE OPIOID SHORT AND LONG-ACTING TABLETS,

LIQUID, CONCENTRATE, SUPPOSITORIES, IV/SUBQ, EPIDURAL, INTRATHECAL

ACTIVE METABOLITES CAN CAUSE TOXICITY IN RENAL FAILURE

STEP THREE OPIOIDS

METHADONE (Dolophine)

• SYNTHETIC• MU AGONIST AND POSSIBLE NMDA

RECEPTOR ANTAGONIST (May help neuropathic pain)

• ORAL/IV/SUBQ

STEP THREE OPIOIDS

METHADONE (Dolophine)

• TRICKY TO TITRATE

VARIABLE CLINICAL EFFECT. (May accumulate and cause lethargy and potential respiratory depression. )

• EFFECTIVE IN LOW DOSES IN SOME PATIENTS WITH POOR RELIEF FROM HIGH DOSE MORPHINE.

STEP THREE OPIOIDS

FENTANYL (Duragesic)

• SHORT-ACTING SYNTHETIC, PACKAGED

AS THREE DAY PATCH

• 25 MCG PATCH APPROXIMATELY

EQUIVALENT TO 15 MG ORAL MORPHINE

• NOT FOR QUICK TITRATION

(ANALGESIC EFFECT PEAKS ABOUT 17 HOURS

AND LINGERS THAT LONG WHEN REMOVED)

• MAY BE ABSORBED QUICKLY IF TEMP

ELEVATION (BEWARE RESPIRATORY

DEPRESSION)

STEP THREE OPIOIDS

FENTANYL

BEWARE ORAL MUCOSAL PRODUCTS:

UNCLEAR DOSING, RAPID ABSORPTION

STEP THREE OPIOIDS

BUPRENORPHINE

(sublingual tablet, transdermal patch)

• CAN BE USED FOR MODERATE TO SEVERE PAIN

• MAY INDUCE WITHDRAWAL IN OPIOID DEPENDENT PATIENTS

ADJUVANTS

IMPORTANT TO TREATMENT OF NEUROPATHIC PAIN

ANTIDEPRESSANTS

ANTICONVULSANTS

ANESTHETICS

ANTIDEPRESSANTS

TRICYCLICS amitriptyline(Elavil) nortriptyline(Pamelor) SSRI’s paroxetine(Paxil) Others: venlafaxine (Effexor) mirtazipine (Remeron) duloxetine (Cymbalta)

ANTICONVULSANTS

• gabapentin (Neurontin)

• pregabalin (Lyrica)

• clonazepam (Klonopin)

ANESTHETICS FOR PAIN• Lidocaine IV, Ointment, Lidoderm Patch• EMLA • Ketamine Oral, IV, Subq

OTHER TOPICAL PREPARATIONS• Capsaicin

• SUMMARY

• CANCER PAIN CAN AND MUST BE RELIEVED

• OBTAIN THOROUGH HISTORY AND PHYSICAL EXAM

• ADMINISTER MEDICATION ON A REGULAR BASIS • ACCORDING TO THE ANALGESIC LADDER• STEP 1. NON-OPIOID +/- ADJUVANT• If pain persists or worsens, go to:• STEP 2. MILD OPIOID + NON-OPIOID +/- ADJUVANT• If pain persists or worsens, go to:• STEP 3. STRONG OPIOID +/- NON-OPIOID+/-ADJUVANT• OFFER EMOTIONAL SUPPORT• REASSESS PAIN AND EFFECTIVENESS OF TREATMENT • FREQUENTLY

PAIN SUMMARY

PAIN MUST BE RELIEVED

THOROUGH HISTORY AND PHYSICAL EXAM

MEDICATION ON A REGULAR BASIS ACCORDING TO THE ANALGESIC LADDER

STEP 1. NON-OPIOID +/- ADJUVANT STEP 2. MILD OPIOID +/- NON-OPIOID +/- ADJUVANT STEP 3. STRONG OPIOID +/- NON-OPIOID+/-ADJUVANT

EMOTIONAL SUPPORT

REASSESS PAIN AND EFFECTIVENESS OF TREATMENT FREQUENTLY

OPIOID EQUIVALENCE

5 MG OF OF IV OR SUBQ MORPHINE EVERY 4 HOURS =

15 MG OF IMMEDIATE RELEASE ORAL MORPHINE EVERY 4 HOURS =

25 MCG FENTANYL PATCH EVERY 3 DAYS

USEFUL REFERENCES

• ASSESSING AND TREATING PAIN; UNIPAC THREE, AAHPM, 2012.

• CANCER PAIN RELIEF, WORLD HEALTH ORGANIZATION, GENEVA, 1986.

• EDUCATION FOR END OF LIFE CARE (EPEC) PROJECT,2003; NORTHWESTERN UNIVERSITY SCHOOL OF MEDICINE created with AMA & ROBERT WOOD JOHNSON FOUNDATION, CHICAGO, ILL.

• FERRANTE, FM; ‘‘Principles of Opioid Pharmacotherapy: Practical Implications of Basic Mechanisms”, J. of PAIN and SYMPTOM MANAGEMENT; May 1996, Vol. 11, No 5.

• FOLEY, KM; “The Treatment of Cancer Pain” ,NEJM;1985, 313:84-95.

• MANAGEMENT OF CANCER PAIN, Clinical Practice Guideline #9; AHCPR Publication #94-0592, March 1994.

• PRIMER OF PALLIATIVE CARE, 5th Edition; AAHPM, 2010.